News

GMB star fights tears live on ITV show as he gives 'devil disease' update
Graeme Souness appeared on Good Morning Britain as he became emotional while speaking about an extremely painful illness.
BioPharma Dive3d
Abeona cell therapy approved by FDA for rare skin condition
Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...
MedPage Today on MSN3d
FDA OKs New Gene Therapy for Debilitating Skin Condition
Patients with the debilitating dermatologic condition are born with COL7A1 mutations in both gene copies, affecting the ...
FDA approves Zevaskyn for rare, genetic skin disorder
The U.S. Food and Drug Administration has approved Abeona Therapeutics' Zevaskyn (prademagene zamikeracel) for patients with ...
Medscape3d
FDA Approves First One-Time Topical Treatment for Recessive Dystrophic Epidermolysis Bullosa Wounds
In a phase 3 trial, 81% of wounds treated with autologous cell sheet-based gene therapy showed ≥ 50% healing at 6 months, ...
Health and Me on MSN3d
FDA Greenlights Zevaskyn for Rare Genetic Skin Condition
With FDA approval, Zevaskyn is set to be a game-changer in the treatment of recessive dystrophic epidermolysis ...
Daily Jang2d
Duchess Sophie sends good wishes to swimmers supporting EB cause
Duchess Sophie is sending good wishes to Graeme and the swim team!As the patron of DEBRA UK, a charity that supports ...
Healio3d
FDA approves Zevaskyn for treatment of recessive dystrophic epidermolysis bullosa
The FDA has approved Zevaskyn for the treatment of recessive dystrophic epidermolysis bullosa, the company announced in a ...
BioSpace3d
Abeona Gets FDA Nod for Rare Skin Disease Gene Therapy
The condition, recessive dystrophic epidermolysis bullosa, causes chronic wounds and has an 84% mortality rate by age 40.
Yahoo Finance4d
Abeona cell therapy approved by FDA for rare skin condition
The agency cleared Abeona Therapeutics’ Zevaskyn for a form of epidermolysis bullosa, a rare disease that makes the skin susceptible to extensive and severe blistering. On a conference call ...